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Available online 30 April 2016Graft rejection and graft-versus-host disease are leading causes of transplant related mortality despite advance-
ments in immunosuppressive therapy. Mesenchymal stem cells (MSCs) offer a promising addition to immuno-
suppressive drugs (ISD), while NK-cells are increasingly used as effector cells in graft-versus-leukemia.
Combined therapy of ISD, NK-cells and/or MSCs is used in clinical practice. Here, we examined the effects of
MSCs and selected ISD (tacrolimus, cyclosporin A, mycophenolic acid, dexamethasone) treatment on early NK-
cell activation.We assessed STAT4 and STAT5 phosphorylation triggered by IL-12 and IL-2, respectively. Further-
more, we determined IFNγ, perforin production and the expression pattern of selected NK-cell receptors. Of all
drugs tested, only dexamethasone inhibited NK-cell STAT4 and STAT5 phosphorylation. All ISD, with the excep-
tion of MPA, signiﬁcantly inhibited IFNγ, and only dexamethasone inhibited upregulation of early activation
markers CD69 and CD25 (IL-2 condition only). MSCs inhibited IL-2 induced NK cell STAT5 phosphorylation,
IFNγ production and CD69 upregulation, and IL-12 induced IFNγ and perforin production.While MSCsmediated
inhibition of CD69 expression was cell contact dependent, inhibition of IFNγ and perforin production, as well as
STAT5 phosphorylation was cell-contact independent. Importantly, dexamethasone augmented MSCs mediated
inhibition of both IL-12 and IL-2 induced CD69 expression and IFNγ production, as well as IL-2 induced STAT5
phosphorylation. Taken together, these novel insights may help the design of future NK-cell and MSCs based
immunotherapy.






hematopoietic stem cell transplantation1. Introduction
Solid organ and hematopoietic stem cell transplantation (HSCT) are
currently life saving treatments for many patients suffering from either
benign or malignant disorders. Leading causes of transplantation-relat-
ed mortality are graft rejection and Graft-versus-Host Disease (GvHD)
[1–3]. These complications are due to an unwanted activity of the im-
mune system. Although T-cells are the primary drivers of acute cellular
rejection, recent studies have claimed natural killer (NK) cell allo-reac-
tivity in inﬂuencing transplantation outcome [4–6]. There is increased
interest in the inﬂuence of NK-cells on clinical outcomes following allo-
geneic transplantation [6].
NK-cells are major effectors of the innate immune system, responsi-
ble for tumor cell and virus-infected cell clearance. A balance between
activatory and inhibitory receptor signaling regulates the function of
NK-cells. While inhibitory receptors suppress NK-cell function,dical center, Dept Laboratory
B Nijmegen., Netherlands.
en).
. This is an open access article underactivatory receptors like CD16, natural cytotoxicity receptors (NCR)
and NKG2D upon recognition of their respective ligands, mediate anti-
body-dependent cytotoxicity, or tumor- and virus-infected cell lysis, re-
spectively. Upon activation NK-cells are not only cytolytic, but also
secrete cytokines that exert a regulatory control on downstream adap-
tive immune responses and inﬂuence the strength and the quality of
the T-cell response [7].
Tominimize the risks associatedwith allo-reactive reactions, immu-
nosuppressive drugs (ISD) are routinely administered after allogeneic
transplantation. Calcineurin inhibitors, such as cyclosporine A (CsA)
and tacrolimus, block the calcineurin pathway by forming complexes
with cyclophilin or FK-binding protein, respectively, preventing the nu-
clear translocation of the nuclear factor of activated T-cells thus
inhibiting transcription of genes leading to dampened T-cell responses
[8,9]. Mycophenolic acid (MPA), the active component of mycopheno-
latemofetil, is an antiproliferative drug that suppresses guanine biosyn-
thesis by inhibiting inosine monophosphate dehydrogenase (IMPDH)
[10]. Glucocorticoids, like dexamethasone, bind glucocorticoid recep-
tors irreversibly forming a complex, which interacts with cellular DNA
in the nucleus and thereby changing gene transcription [11,12]. Steroids
impinge on various stages of antigen presentation, cytokine productionthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and immune response [13,14].
Over the last two decades, the scientiﬁc and clinical interest in mes-
enchymal stem cells (MSCs) has increased exponentially, based on their
tissue repair and immunomodulatory properties. The capacity of MSCs
to broadly inhibit the activity of the major components of the innate
and adaptive immune system makes them ideal candidates for toler-
ance-inducing cell therapy [15,16]. MSCs have pro-angiogenic,
cytoprotective, and antiﬁbrotic properties, which can prolong graft sur-
vival and even induce tolerance after solid organ transplantation [17,
18]. MSCs are currently used for the prevention and treatment of
acute and chronic GvHD, after the success of a multicenter phase II
study, where MSCs were used to treat steroid-resistant GvHD in alloge-
neic HSCT [19].
Alreadywe, amongst others, reported on the effects of ISD andMSCs
onNK-cells and demonstrated that depending on the drug, bothNK-cell
proliferation and function can be impaired after 5–7 days of culture [13,
20–22]. IL-2 and IL-12 are critical cytokines involved in the maturation,
activation, and survival of NK-cells [23]. As the period of contact with
MSCs is limited due to rapid disappearance of these cells after infusion
and IL-2/IL-12 induced NK-cell responses are almost immediate [24,
25], we focused on the differential effects of ISD and MSCs on the early
activation events in IL-2 or IL-12 stimulated NK-cells. In addition, it
has been demonstrated that once activated, NK-cells kill MSCs even
when pre-incubatedwith ISD [26].We assessed STAT4 and STAT5 phos-
phorylation triggered by IL-12 and IL-2, respectively, IFNγ and perforin
production, the surface expression of activatory and inhibitory NK re-
ceptors, as well as the early activation markers, CD25 and CD69 [27].
We found that of the drugs tested, dexamethasone was most effective
in inhibiting early NK-cell activation. In addition, MSCs were able to in-
hibit NK-cell activation already after a short co-culture of 16h. Impor-
tantly, dexamethasone did not interfere with MSCs mediated
inhibition of NK-cells, and even augmented the inhibitory effect of
MSCs on CD69expression, IFNγproduction and STAT5 phosphorylation.
2. Materials and methods
2.1. Sampling
NK-cells were isolated from buffy coats of healthy blood donors pur-
chased from Sanquin Blood Supply Foundation, region South-East, Nij-
megen, the Netherlands (http://www.sanquin.nl/bloed-geven/ik-geef-
bloed/bloedbanklocaties/nijmegen/); buffy coats were obtained upon
written consent from the donor for scientiﬁc use, and according to
Dutch law. MSCs were generated from the washings of bone marrow
collection bags, surplus material obtained as part of stem cell transplant
procedures performed at the Radbouduniversitymedical centre, Nijme-
gen, The Netherlands. The use of these samples was according to dutch
legislation on sample collection, manipulation and personal data pro-
tection of surplus material (code “Nader gebruik van
lichaamsmateriaal”; part of the Code “Goed gebruik van
lichaamsmateriaal”). Additional review for the use of such samples by
the Radboudumc institutional review board was wavered.
2.2. NK-cell isolation and culture conditions
NK-cells were isolated using the MACS NK-cell isolation kit accord-
ing to the manufacturer's instructions (Miltenyi Biotec, Bergisch
Gladbach, Germany). Typically, CD56+/CD3- NK-cell purity was be-
tween 85 and 95%. NK-cellswere cultured in U-bottomed 96-well plates
(Greiner bio-one, Frickenhausen, Germany) at the rate of 2x1.0E5 cells
per well in RPMI 1640 medium supplemented with penicillin (100U/
ml), streptomycin (100μg/ml), glutamax (2mM) pyruvate (1mM) (all
from Gibco, LifeTechnology, Bleiswijk, Netherlands) and 10% fetal calf
serum (Greiner Bio-one). A low concentration of IL-15 (5ng/ml,
BioSource International, Camarillo, CA, USA) was added to all culturemedia used to maintain NK-cell survival and homeostatic properties
[28–30]. NK-cells were stimulated with either 50ng/mL IL-12 (Gibco,
Life technologies) or 100U/mL IL-2 (Chiron, Amsterdam, the Nether-
lands) and incubated at 37 °C, 95% humidity and 5% CO2 for 16h. IL-12
induces STAT4 phosphorylation and increases IFNγ production by NK-
cells [24] while IL-2 induces STAT5 phosphorylation and increases NK-
cell cytotoxicity [11,14]. Upon culture, NK cell viability, as checked by
ﬁx viability dye staining, was typically between 55 and 80%. To analyze
the effect of ISD, NK-cells were stimulated as described above in the ab-
sence or presence of ISD. For each of the drugs, two concentrationswere
used; dexamethasone (10ng/ml and 100ng/ml), tacrolimus (10ng/ml
and 40ng/ml), CsA (100ng/ml and 1000ng/ml) and MPA (100ng/ml
and 500ng/ml). ISD dose range was chosen based on therapeutic
serum levels used at our center and are in concert with our previous
work [20,31]. From the dose range experiments in those studies we se-
lected the most optimal (high/low) concentration in vitro, in order to
achieve the highest discriminative power. Analysis was performed
after 16h of culture.
2.3. MSCs isolation and expansion
MSCswere generated from the washings of BoneMarrow (BM) Col-
lection Bags after transplantation [32]. BM-derived MNC obtained by
density gradient centrifugation were cultured in Dulbecco's modiﬁed
Eagle medium (Lonza, Switzerland), supplemented with 10% pooled
Human Platelet Lysate. Cells were cultured at 37 °C in a humidiﬁed at-
mosphere with 5% CO2, and the culture medium was changed twice
per week. Upon reaching 80% conﬂuence, MSCs were detached with
trypsin-EDTA (Lonza) and re-seeded at 3 x 1.0E3cells/cm2 for further
expansion. To ensure macrophage and monocyte depletion, cell purity
and same cellular life span while avoiding cellular senescence, only
MSCs between passages 3 and 4 were used for experiments. MSCs
were characterized by direct or indirect single ﬂuorescence analysis,
using commercially available monoclonal antibodies CD29, CD105,
CD106, and CD166 (Ancell, MN, USA); HLA class I and II, CD14, CD34,
CD45, CD44, and CD73 (BD Biosciences, San Jose, CA, USA).MSCs gener-
ated fulﬁlled the baseline criteria deﬁned by the international society of
cell therapy [33]; adherence to plastic, mesodermal phenotypewith the
absence of hematopoietic cell markers, and multi-lineage differentia-
tion. MSCs were positive for all mesodermal markers CD73,CD105,
CD106, CD166, CD29 and CD44, while negative for hematopoietic cell
markers; CD45, CD34 and CD14. In addition, they were positive for
HLA class I, and cells did not upregulate HLA class II after in vitro culture.
2.4. NK-MSCs co-cultures
MSCs were sub-plated in ﬂat bottom 96 well plates (Greiner Bio-
one) at 2x1.0E4 cell per well and NK-cells were added after 24h to
allow forMSCs adherence to the plates. NK-cells andMSCswere co-cul-
tured in a 10:1 ratio in 200uL culturemedium (mentioned above) in the
absence or presence of dexamethasone (Dex, 10ng/ml and 100ng/ml).
Initially, NK-cell to MSCs ratios of 5:1 and 10:1 were tested; as a ratio
of 10:1 revealed clear effects, this ratio was used in subsequent experi-
ments. NK-cells were collected as the non-adherent fraction of the co-
culture, leaving MSCs adherent to the plastic well. All further
ﬂowcytometric analysis was performed on the CD56 +/CD3- gate as
only 1% of our MSCs expressed CD56.
2.5. Phenotypic analysis
To assess NK activation status, we analyzed STAT4/5 phosphoryla-
tion, and CD25andCD69 surfacemarker expression. After 16hof culture
cells were washed once with FACS buffer (PBS, 0.2% BSA) and ﬁxed for
10 min at 37 °C with pre-warmed ﬁxation buffer (0.5×) (BD Cytoﬁx,
BD Biosciences). Fixed cells were permeabilized with 1× perme-
abilization buffer IV (BD TM Phosﬂow, BD Biosciences) and kept on ice
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PC7 (A21692), CD3-PC5 (A07749) and CD69-ECD (6607110) (Beckman
Coulter, Woerden Netherlands), CD25-PE (555432) and STAT4
(558136) or STAT5 (612598) Alexa 488 from BD Biosciences (Breda,
Netherlands). NK-cells were incubated for 20 min with the antibody
mixture diluted with FACS buffer. Stained cells were analyzed with
the FC500 Flow Cytometer (Beckman Coulter, Woerden, Netherlands)
and data analyzed with Beckman Coulter Kaluza software version 1.2.
For intracellular analysis of IFNγ and perforin production, NK-cells
were stimulated for 4h with 12,5ng/ml phorbol-12-myristate-13-ace-
tate (Sigma, Zwijndrecht, Netherlands), 500ng/ml ionomycin and 5μg/
ml brefeldine A (BD Biosciences) after 16h of culture. Anti-IFNγ PC7
(25–7319-82; BD Biosciences), anti-perforin PE (12–9994-42;
eBioscience), CD56-PC5 A07784(Beckman Coulter) and CD3-ECD
(A07748; Beckman Coulter) were used for staining.
For phenotypic analysis of NK-cell surface receptors, cells obtained
under different culture conditions were phenotypically analyzed on
the Navios ﬂowcytometer (Beckman Coulter) using the 10-color ﬂow
cytometry panel: CD16 FITC (Dako, Heverlee, Belgium), CD159c PE
(NKG2C) (R&D, Abingdon, UK), CD336 PE (NKp44), CD3 ECD, CD337
PC5.5 (NKp30), CD85j PC5.5 (ILT2), CD335 PC7 (NKp46), CD158b1/b2,
j PC7 (KIR2DL2/S2/L3), CD314 APC (NKG2D), CD158e1/e2 APC
(KIR3DL1/S1), CD244 APC AF700 (2B4), CD158a,h APC AF700
(KIR2DL1/S1), CD56 APC AF750, CD161 PB, CD159a PB(NKG2A) and
CD45 (all provided by Beckman Coulter). Samples were measured on
the Beckman Coulter Navios and data analyzed with Kaluza software
v1.2. Appropriate isotype controls were used for gate setting. Supple-
mental Fig. 1 in the online version at http://dx.doi.org/10.1016/j.trim.
2016.04.008.. shows dot plot examples of gating strategy and marker
staining.
2.6. Transwell and blocking experiments
MSCs were plated in 24-well plates (Greiner Bio-one) at the rate of
3x1.0E4 cells per well and 24 h later after cell adhesion, 3x1.0E5 freshly
isolated NK-cells were added to the MSCs culture at a 10:1 ratio per
well, either in direct cellular contact or separated by 0.4μm pore inserts
(Geiner Bio-one) in 600μL of media. Since PGE2 was shown to play a
role in MSCs mediated NK-cell inhibition [34], 5μM NS-398 (Sigma,
Zwijndrecht, Netherlands), an inhibitor of PGE2 synthesis, was added
to both the NK-MSCs co-cultures under the conditions mentioned
above. NK-cells were then analyzed for surface receptors and function,
as previously mentioned.
2.7. Statistical analysis
Statistical tests were performed using Graph Pad Prism version 6.01
for windows (GraphPad software, La Jolla California USA, www.
graphpad.com). Data are represented as mean± SEM. Statistical differ-
ences were calculated using the non-parametric Friedman test for dif-
ferences in treatment, with Dunn's post-hoc test for multiple
comparisons, or the Wilcoxon matched pairs signed rank test, where
applicable. Differences were considered signiﬁcant at p b 0.05(*), p b
0.01(**).
3. Results
3.1. Dexamethasone inhibits STAT5 signaling and IFNγ secretion by activat-
ed NK-cells and inhibits the expression of early activation markers
To evaluate the effect of selected ISD (dexamethasone, tacrolimus,
CsA and MPA) on STAT4 and STAT5 phosphorylation, peripheral blood
NK-cells were isolated and activated by IL-2 + IL-15 or IL-12 + IL-15
for 16 h, in the presence or absence of the drugs. NK-cells were then
ﬁxed and stained for intracellular STAT phosphorylation, IFNγ and
perforin production (see Supplemental Fig. 1 in the online version athttp://dx.doi.org/10.1016/j.trim.2016.04.008. for dot plot examples of
gating strategy and marker staining). In the absence of the drugs, IL-
12 induced STAT4 phosphorylation in about 60% of NK-cells (mean ±
SEM 60.7% ± 9.2), and IL-2 induced STAT5 phosphorylation in 74% of
NK-cells (mean ± SEM 73.7% ± 5.0) (Fig. 1A).
Of the drugs tested, dexamethasonewas the only ISD capable of sig-
niﬁcantly inhibiting both STAT4 and STAT5 phosphorylation. Both con-
centrations of dexamethasone (10ng/ml and 100ng/ml) signiﬁcantly
inhibited IL-12 induced STAT4 (mean ± SEM 40% ± 11.3 and 48% ±
8.7, respectively) and IL-2 induced STAT5 signaling (mean ± SEM 54%
± 4.3 and 42% ± 9.3, respectively) (Fig. 1A). IL-12 stimulation induced
higher percentages of IFNγ producing NK-cells (mean mean ± SEM
63.2% ± 5.2) than IL-2 stimulation (mean ± SEM 46.4% ± 6.8). All
ISD, except MPA, inhibited IFNγ production by NK-cells activated by ei-
ther IL-2 or IL-12 (Fig. 1A). Under the conditions tested, dexamethasone
had the highest inhibitory effect on IL-12 induced IFNγ production
(lowest mean percentage of IFNγ producing cells 33% ± 7.5 (10ng/
ml) and 29%±6.0 (100ng/ml), respectively), while CsA had the highest
inhibitory effect on IL-2 induced IFNγ production (mean ± SEM 5% ±
1.1 (100ng/ml) and 5% ± 2.0 (1000ng/ml)). None of the drugs used
was able to inhibit perforin production by activated NK-cells. Surpris-
ingly, the addition of tacrolimus increased perforin production by IL-2
stimulated NK-cells (Fig. 1A).
The effect of ISD on NK-cell phenotype was further evaluated by
measuring the surface expression/up-regulation of the early activation
markers CD25 and CD69, aswell as activatory and inhibitory NK-cell re-
ceptors, using the abovementioned culture conditions. Dexamethasone
was the only ISD capable of signiﬁcantly affecting NK-cell phenotype in
both IL-12 and IL-2 conditions. Both concentrations of dexamethasone
down-regulated the expression level of the early activation markers
CD69 and CD25 on IL-12 and IL-2 (only signiﬁcant in case of 100ng/
ml) activatedNK-cells (Fig. 1B). Noneof the activatory NK-cell receptors
tested (NKp30, NKp44, NKp46, NKG2D, NKG2C and 2B4) and inhibitory
NK-cell receptors (NKG2A, CD85 and KIR expression) were signiﬁcantly
affected by any of the ISD used, although there was a trend towards
lower NKp44 levels in the dexamethasone treated condition (data not
shown).
3.2. MSCs inhibit early activation by NK-cells
Previously,MSCswere shown to inhibit NK-cell proliferation and cy-
totoxicity after 5–7 days in vitro cultures [22]. Here, we addressed the
question whether MSCs might already affect NK-cells very shortly
after contact (16h), based on their “hit and go” effect. This set up
allowed us also to assess immediate STAT phosphorylation.STAT4 and
STAT5 phosphorylation, perforin and IFNγ production, as well as CD25
and CD69 expression were measured after overnight NK-cell stimula-
tion with either IL-12 or IL-2 (as described above) in the absence or
presence of MSCs. At this early time point in culture, MSCs had a slight,
but signiﬁcant inhibitory effect on STAT5 phosphorylation in NK-cells
stimulated by IL-2, while they had no effect on STAT4 phosphorylation
in IL-12 stimulated NK-cells (Fig.2A).
MSCs also inhibited IFNγ production in IL-12 stimulated NK cells
(mean ± SEM: 63.3% ± 5.1 versus47.5% ± 7.1) and IL-2 stimulated
NK cells (46.4%±6.8 versus 20.9%±6.8). Additionally, perforin produc-
tion was inhibited in the IL-12 condition (mean± SEM: 66.7± 4.0 ver-
sus 51% ± 7.9).
The addition ofMSCs to theNK-cell culture prevented the typical up-
regulation of the early activation marker CD69 under IL-2 and IL-12
(trend) stimulatory conditions, however CD25 expression was not af-
fected (Fig. 2A). It was previously demonstrated that MSCs prevent
the up-regulation of IL-2 induced NK-cell activatory receptors after 7
days of co-culture [22,35]. After 16 h of co-culture, we observed a
trend towards lower levels of cells positive for activatory receptors, par-
ticularly NKp44, but this effect did not reach statistical signiﬁcance.
MSCs did not inﬂuence NK-cell inhibitory receptors (Fig. 2B).
Fig. 1. Effect of selected immunosuppressive drugs onNK-cell phenotype and functionalmarkers. IsolatedNK-cells from healthy donorswere stimulatedwith either 50ng/ml IL-12 or
100U/ml IL-2 for 16 h in a U-bottomed 96-well plate in 200ul of culture medium at a rate of 2 × 10^5cell/well, and cultured in the presence of a low dose IL-15 (5ng/ml), in the absence
(ctlr) or presence of immunosuppressive drugs (dexamethasone (Dex), tacrolimus (Tac), cyclosporin (CsA) or mycophenolic acid (MPA)). A) Percentage of NK-cells positive for STAT4/5
phosphorylation, IFN-γ or perforin after stimulation with either IL-12 (upper panel) or IL-2 (lower panel) in the presence or absence of drugs. Intracellular IFN-γ and perforin were
measured after an additional stimulus with PMA/ionomycin at the time of analysis. B) Expression levels (MFI) of early activation makers CD25 and CD69 on NK-cells after stimulation
with either IL-12 or IL-2 and in the presence or absence of drugs. C). Percentage of NK-cells expressing activating NK-cell receptors after stimulation with either IL-12 (upper panel) or
IL-2 (lower panel) in the presence or absence of drugs. Data are represented as mean ± SEM of 6–9 independent experiments. Statistical differences were calculated using the non-
parametric Friedman test for differences in treatment conditions, with Dunn's post-hoc test for multiple comparisons. Differences were considered signiﬁcant at p b 0.05(*), p b 0.01(**).
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Fig. 2. Effect of mesenchymal stem cells on NK-cell phenotype and functional markers. Mesenchymal stem cells (MSCs) were cultured in ﬂat-bottomed 96 well plates at a rate of
2 × 10^4cells/well, in 200ul of culture medium. To allow for adhesion of the MSCs, 2 × 10^5 NK-cells were added after 24 h. NK-cells cultured without MSCs were used as control. NK-
cells were stimulated with either 50ng/ml IL-12 or 100U/ml IL-2 for 16h in the presence of a low dose IL-15 (5ng/ml). A) Percentage of NK-cells positive for phosphorylated STAT4/5,
IFN-γ or perforin (left and middle panel) and expression levels (MFI) of early activation makers CD25 and CD69 on NK-cells (right panel) after stimulation with either IL-12 (upper
panel) or IL-2 (lower panel), in the presence or absence of MSCs. Intracellular IFN-γ and perforin were measured after an additional stimulus with PMA/ionomycin at the time of
analysis. B) Percentage of NK-cells expressing activatory and/or inhibitory NK-cell receptors after stimulation with either IL-12 (upper panel) or IL-2 (lower panel) in the presence or
absence of MSCs. Data are represented as mean ± SEM of 6–9(A) or 3–5 (B) independent experiments. Statistical differences were calculated using the non-parametric Wilcoxon
matched pairs signed rank test and differences were considered signiﬁcant at p b 0.05(*), p b 0.01(**).
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Since dexamethasone was the most potent ISD inﬂuencing NK-cell
function and phenotype and since most patients undergoing transplan-
tation are regularly under steroid therapy, we questioned whether
dexamethasone may affect/interfere with the observed inhibitory ef-
fects of MSCs on NK-cells. We co-cultured MSCs and NK-cells under
the same culture conditions described above in the absence and pres-
ence of dexamethasone (10ng/ml and 100ng/ml) andmeasured NK pa-
rameters affected by MSCs in our culture set-up (see Fig. 2). The
addition of dexamethasone to the NK-MSCs co-cultures did not inter-
fere with the inhibitory effect of MSCs on NK-cells, as none of the affect-
ed parameters were signiﬁcantly up-regulated in either IL-12 or IL-2
stimulation conditions (Fig 3). (See Fig. 4.)
Interestingly, in both IL-12 and IL-2 stimulated NK-cells the addition
of dexamethasone to NK-MSCs co-cultures augmented the inhibitory
effect of MSCs on IFNγ secretion and CD69 expression. Under IL-2 stim-
ulation, dexamethasone augmented the inhibition of STAT5 phosphory-
lation by MSCs. There was no added effect of dexamethasone on the
inhibition of perforin.
3.4. Distinct contact dependency of MSCs-mediated inhibitory effects on
NK-cells
Previously, in 5–7 day cultures, the inhibitory effect of MSCs on NK-
cells was shown to be mediated via both cell-cell contact and soluble
mediators, including PGE2 [34,36–38]. We here show that suppressive
effects of MSCs was already exerted after 16 h of co-culture, and in-
volved the inhibition of STAT phosphorylation under IL-2, but not
under IL-12 conditions. So we set out to investigate whether cell-cell
contact and/or soluble factors were involved in these early stages of in-
teraction. We used a 24-well plate transwell culture system; due to the
distinct culture conditions from the regular 96 well set-up (used forFig. 3. Combined effects of dexamethasone and MSCs on activated NK-cells.Mesenchymal s
well, in 200ul of culturemedium. To allow for adhesion of theMSCs, 2 × 10^5NK-cells were add
were stimulated with either 50ng/ml IL-12 (upper panel) or 100U/ml IL-2 (lower panel) for
measured after an additional stimulus with PMA/ionomycin at the time of analysis. Data are r
calculated using Wilcoxon matched pairs signed rank test, comparing each condition to the coFigs. 1–3), this resulted in a somewhat less activated NK-cell population
upon cytokine stimulation. In IL-12 stimulated co-cultures, cellular con-
tactwas not needed to achieve the inhibitory effect ofMSCs on IFNγ and
perforin production, while inhibition of CD69 expression was contact
dependent. In IL-2 stimulated cultures, inhibition of STAT5 phosphory-
lation and IFNγ productionwas not contact dependent, while inhibition
of CD69 was only achieved through contact dependent interactions.
In a further attempt to investigate whether PGE2 was involved as
soluble factor in MSCs mediated inhibition of NK-cells, we added the
PGE2 blocker NS398 to the transwell set up. Fromprevious experiments
we learned that addition of NS398 blocked PGE2 secretion byMSCs [22,
34]. Here, we observed that the addition of NS398 had no effect on
MSCs-mediated NK-cell inhibition (Fig. 5).
4. Discussion
Transplant recipients receive life-long administration of immuno-
suppressive drugs (ISD), butmuch is yet to be learned regarding the im-
pact of these drugs on NK-cells [21], innate immune cells that recently
gained interest for their allo-reactive and therapeutic potential [6].
Next to ISD, MSCs are currently administered for the prophylaxis and
treatment of acute and chronic GvHD [39] and more recently to control
solid organ transplant rejections [40].
Already we, amongst others, reported on the long term in vitro ef-
fects of ISD and MSCs on NK-cells and demonstrated that depending
on the drug, both NK-cell proliferation and function is impaired after
5–7 days of culture [13,20–22]. Further to our previous data, herewe fo-
cused on early NK-cell activation markers, as in vivo contact with MSCs
is likely limited due to rapid disappearance of these cells after infusion,
and cytokine induced NK-cell responses are almost immediate [24,25].
We here show that dexamethasone is highly efﬁcient in inhibiting
early NK-cell activation and function under both IL-12 and IL-2 stimula-
tory conditions. We also demonstrate that MSCs are able to inhibittem cells (MSCs) were cultured in ﬂat-bottomed 96 well plates at a rate of 2 × 10^4cells/
ed after 24 h, in the absence or presence of 10ng/ml or100ng/ml dexamethasone. NK-cells
16h in the presence of a low dose IL-15 (5ng/ml). Intracellular IFNγ and perforin were
epresented as mean ± SEM of 6–8 independent experiments. Statistical differences were
ntrol. Differences were considered signiﬁcant at p b 0.05(⁎), p b 0.01(⁎⁎).
Fig. 4. Contact dependency of the MSCs-mediated inhibitory effect on NK-cells. NK-cells were co-cultured with mesenchymal stem cells (MSCs) at a rate of 3 × 10^5 NK-cells to
3 × 10^4 MSCs (10:1 ratio) in ﬂat-bottomed 24-well plates, in a volume of 600ul/well. MSCs were left for 24h to allow for adhesion before NK-cells were added either directly to the
well (contact) or placed in a 24-well plate 0.4μm pore-size transwell insert (no contact/transwell). NK-cells were stimulated with either 50ng/ml IL-12 or 100U/ml IL-2 for 16 h, in the
presence of a low dose IL-15 (5ng/ml). NK-cells only were included as control. Figure upper panel shows IL-12 induced percentage ofIFNγ and perforin producing NK cells and NK cell
expression levels of CD69 (MFI); the lower panel shows IL-2 induced percentage of cells positive for phosphorylated STAT5 and IFNγ production, and NK cell expression levels of CD69
(MFI), in cultures with NK-cells only, NK-cells directly into contact with MSCs and NK-cells separated from MSCs by an insert. Intracellular IFN-γ and perforin were measured after an
additional stimulus with PMA/ionomycin at the time of analysis. Data are represented as mean ± SEM of 8–11 independent experiments. Statistical differences were calculated using
the non-parametric Wilcoxon matched pairs signed rank test, comparing each condition with the control. Differences were considered signiﬁcant at p b 0.05(*), p b 0.01(**).
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ture period of 16h, irrespective of the cytokine stimulus. While inhibi-
tion of NK-cell surface markers and receptors appears to require cell-
cell contact, inhibition of IFNγ and perforin production wasmostly like-
ly through soluble mediators. Importantly, dexamethasone did not in-
terfere with the immunosuppressive properties of MSCs, and the co-
administration of both agents even augmented the inhibitory effect.
Several studies investigated the interaction between MSCs and NK-
cells [22,35,41–43], most of which demonstrated that MSCs do inhibit
NK-cell function. MSCs were claimed to prevent IL-2, but not IL-12 in-
duced NK-cell proliferation, cytotoxicity, and cytokine production [22,
35]. However all the available data indicate a minimum NK-MSCs co-
culture time of at least 5–7 days to demonstrate the effect. We here
add data showing that even after brief contact MSCs can affect both
NK-cell phenotype and inhibit NK-cell function.
Of the ISD tested, dexamethasone was the only one capable of
inhibiting both STAT4 and STAT5 phosphorylation in both IL-12 and
IL-2 activated NK-cells, respectively. The ability of dexamethasone to in-
hibit JAK-STAT signaling by IL-2 and related cytokines, suggests that glu-
cocorticoids exert their immunosuppressive properties by inhibiting
activation upstream in the IL-2/IL-12 signaling pathway [11].The inabil-
ity of other ISD tested (CsA, tacrolimus and MPA) to inhibit STAT4 and
STAT5 phosphorylation implies that they exert their effects on NK-
cells further downstream the cytokine activation pathway.All ISD test-
ed, with the exception of MPA were able to signiﬁcantly suppress
IFNγ production by either IL-2 or IL-12 activated NK-cells, similar to
our previous results on long term culturing [20]. Our data demonstrateda surprising increase in perforin production by IL-2 (but not IL-12) acti-
vated NK-cells exposed to tacrolimus. Morteau et al. [44] previously re-
ported a number of contradictory observations on the effects of
tacrolimus on NK cell functions, ranging from inhibition to stimulation,
indicating that the immunosuppressive effect of tacrolimus on NK-cell
function is still poorly understood and requires additional study.
Notably, dexamethasone was the only drug capable of affecting NK-
cell activation markers CD69 and CD25. In concert with our previous in
vitro [20] and ex vivo [45] results, treatment of NK-cells with CsA had a
minimal effect on NK-cell receptor expression. Also in HSCT patients
who did not receive steroids, or in patients tested before any steroid
treatment while on CsA therapy, NK-cell phenotype and function were
not signiﬁcantly altered [13]. In our hands MPA had no effect on NK-
cell activation and function after 16 h of culture. Previously, we showed
in 7day cultures [20], that MPA had a strong inhibitory effect on NK-cell
proliferation, probably due to inhibition of IMPDH. Apparently MPA ef-
ﬁciently inhibits long-term induced NK-cell proliferation, but not the
early activating signaling cascades.
Amongst others, MSCs signiﬁcantly inhibited IFNγ production by
both IL-12 and IL-2 activated NK-cells. This is in contrast to Thomas
and colleagues [38], who demonstrated in 24-h cultures that MSCs en-
hanced IFNγ secretion by NK-cells that were activated by low dose IL-
12 combinedwith IL-18. This would suggest that the nature of the cyto-
kine stimulus received by theNKcells determines the outcome of the ef-
fect that MSCs might have on those cells.
There is still controversy about themechanism bywhichMSCs exert
their inhibitory action on NK-cells, both soluble mediators and direct
Fig. 5. The PGE2 blocker NS398was used to assess a possible effect of MCS derived PGE2 on NK cells (n= 3) NK-cells were co-cultured with mesenchymal stem cells (MSCs) at a ratio of
3 × 10^5NK-cells to 3 × 10^4MSCs (10:1 ratio) in ﬂat-bottomed 24-well plates, in a volume of 600ul/well. MSCswere left for 24h to allow for adhesion before NK-cells were added either
directly to the well (contact) or placed in a 24-well plate 0.4μmpore-size transwell insert (no contact/transwell). NK-cells were stimulated with either 50ng/ml IL-12 or 100U/ml IL-2 for
16 h, in the presence of a low dose IL-15 (5ng/ml). NK-cells only were included as control. A. Example dot plot showing % of perforin positive CD56+ NK cells in the different culture
conditions. B.Percentages of NK cells positive for selected markers under IL-2 (upper panel) or IL-12 (lower panel stimulated conditions (contact and transwell) and in the presence or
absence of NS398. Data were analyzed using a non-parametric Wilcoxon matched-pairs signed rank test. No signiﬁcant differences were found.
8 C.M. Michelo et al. / Transplant Immunology 37 (2016) 1–9cellular contact have been implicated [46]. There is mounting evidence
that MSCs perform a “hit and go” action upon in vivo infusion.
Here we showed that for inhibition of early activation markers cell-
cell contact is needed, whereas soluble mediators affected other func-
tions. We previously demonstrated that PGE2 plays a role in MSCs me-
diated modulation of NK-cells [22,47] after 5 days of co-culture. In the
current study using short-term co-cultures, blocking of PGE2 secretion
by MSCs by the PGE2 blocker NS398, did not reverse the inhibitory ef-
fects. This may be explained by the fact that PGE2 secretion by MSCs
at that time point is simply too low, as PGE2 secretion is enhanced
upon direct contact with NK-cells, and cumulative levels are increasing
with time [34]. In the current experimental setting, PGE2 thus played a
minimal role and other factors are likely to be involved. Interestingly
dexamethasone did not interfere with the inhibitory effect of MSCs on
NK-cells, but it augmented the inhibitory effect of MSCs on STAT5 phos-
phorylation, CD69 surface expression and IFNγ production. This sug-
gests that MSCs and dexamethasone use complementary routes of
suppression. Recently, it was shown that dexamethasone augments
MSCs expression of indoleamine-2.3-dioxygenase (IDO), a primaryme-
diator of MSCs immunomodulatory function, followed by enhanced
MSCs derived IFNγ secretion that activates the release of immunosup-
pressive factors [48]. IDO has been implicated in promoting both phys-
iological and pathological tolerance and is over-expressed in solid
tumors, promoting tolerance towards tumor antigens [49].In conclusion, our results provide evidence that MSCs and dexa-
methasone are efﬁcient in the inhibition of early cytokine induced NK
cell activation. In contrast to other ISD treatments, viability, metabolic
activity, andmorphology of MSCs is not signiﬁcantly impacted by expo-
sure to awide range of corticosteroid concentrations [48].Due to distinct
mechanisms of action, the combination of steroids andMSCsmay offer a
promising therapeutic regimen for the enhancement of solid graft sur-
vival, and potentially for the treatment ofGvHD. However, it should be
noted that this could have negative effects on the NK-mediated GVL ef-
fect, particularly in the haploidentical HSC transplantation setting.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.trim.2016.04.008.
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